Company intelligence / Profile preview
DeFloria
Littleton, Colorado, United Statesdefloria.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DeFloria has developed AJA001, an orally delivered, full-spectrum multi-cannabinoid botanical drug derived from Charlotte’s Web proprietary hemp genetics. The company received FDA IND clearance to proceed with Phase 2 clinical trials targeting behavioral symptoms of ASD. Early studies have focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants. The upcoming Phase 2 trial will assess efficacy and dosing in adolescents and young adults with ASD. No commercial products are yet approved.
- Therapeutic areas
- Psychiatry
- Modalities
- Full-spectrum botanical hemp extract (multi-cannabinoid formulation)Oral cannabinoid drug (CBD and other cannabinoids)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ajna BioSciences PBCCharlotte's Web Holdings Inc.British American Tobacco PLC (BAT)
Beyond the preview
Go deeper on DeFloria.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DeFloria.